Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age

INTRODUCTION: The efficacy and safety of vedolizumab, a gut-selective α(4)β(7) integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Yajnik, Vijay, Khan, Nabeel, Dubinsky, Marla, Axler, Jeffrey, James, Alexandra, Abhyankar, Brihad, Lasch, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331094/
https://www.ncbi.nlm.nih.gov/pubmed/28070861
http://dx.doi.org/10.1007/s12325-016-0467-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331094/
https://www.ncbi.nlm.nih.gov/pubmed/28070861
http://dx.doi.org/10.1007/s12325-016-0467-6

Ejemplares similares